Product
Efgartigimod PH20 SC
2 clinical trials
2 indications
Indication
bioequivalenceClinical trial
A Phase 2 Trial to Investigate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 SC in Adult Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)Status: Completed, Estimated PCD: 2023-05-11
Clinical trial
A Phase 1, Randomized, Open-label, Parallel-Group, Single-Dose, Bioequivalence Study of Efgartigimod PH20 SC Administered Via a Prefilled Syringe Versus a Vial + Syringe Presentation in Healthy AdultsStatus: Completed, Estimated PCD: 2023-05-12